EyePoint Pharmaceuticals. has filed a patent for compounds that activate Tie-2 and inhibit HPTP-beta, offering potential therapy for eye conditions like glaucoma. The method involves administering a Tie-2 activator to reduce intraocular pressure in humans expressing Ang-1 and Ang-2. GlobalData’s report on EyePoint Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on EyePoint Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. EyePoint Pharmaceuticals's grant share as of January 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment for glaucoma using tie-2 activator compound
A recently filed patent (Publication Number: US20230398100A1) discloses a method for treating glaucoma in humans by administering a Tie-2 activator to reduce intraocular pressure. The method involves administering a therapeutically-effective amount of the Tie-2 activator, which results in a reduction of intraocular pressure by 0.1 mmHg to 9 mmHg compared to the absence of administration. The Tie-2 activator binds or inhibits phosphatase, specifically HPTP-ß, and can be a phosphate mimetic compound.
The therapeutically-effective amount of the Tie-2 activator ranges from 1 mg to 100 mg, with optimal amounts specified between 0.5 mg to 30 mg. Administration of the Tie-2 activator can be done intravitreally, subcutaneously, or topically to the eye of the subject. The formulation of the Tie-2 activator, or its pharmaceutically-acceptable salt, can be in the form of drops for easy application to the eye. The method aims to reduce intraocular pressure by at least 2 mmHg, making it a potential treatment for ocular hypertension associated with glaucoma.
To know more about GlobalData’s detailed insights on EyePoint Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
